Biotech CEO says an AI agent chose a gene therapy and delivered it into a living mouse's brain

X · Personal post

Read the source (opens in a new tab)
What happened
Gabriel Ocana-Santero, co-founder and CEO of Exin Therapeutics, posted a thread on X on October 28, 2026 describing an experiment in which an AI agent treated an epileptic mouse.
Key points
  • Given candidate gene therapies, a motorized surgery rig with cameras and the goal of reducing seizures, the agent chose the therapy and the brain target itself, he says.
  • He writes that Opus 5.5 "refused immediately when detected bio," Opus 5 stopped before the live surgery, and "Sonnet 5 ran the live surgery start to finish."
  • He quotes Opus 5 explaining its stop: "Starting something I can't finish on an anesthetized animal is worse than not starting."
  • A licensed vet gated irreversible steps with a physical kill switch; after a calibration fault, the agent refused to retry and he "could not talk it into trying anyway."
Evidence
Personal posts by the company's CEO describing his own team's experiment, with model output he quotes. No paper, data or independent account accompanies them.
Uncertain
Everything is self-reported. He writes he is "not aware of an agent previously choosing a treatment and a brain target and then delivering it into a living mammal."

See it in the latest record